commonly used for autologous hematopoietic transplants. PBSCs are also now being used for
some syngeneic and allogeneic hematopoietic transplants involving HLA-matched sibling
donors. However, many issues remain unanswered about the use of PBSCs for allogeneic
transplants and the effects of filgrastim on healthy individuals. The purpose of this study
is to determine the effectiveness of filgrastim stimulated PBSCs in hematopoietic cell
transplants involving unrelated donors and to determine the effects of this donation process
on unrelated stem cell donors.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.